phrykt

Acrivon Therapeutics, Inc. (ACRV): who owns it and who trades it

As of Nov 16, 2026, ACRV insiders reported 11 open-market sales worth $41.4K and 3 purchases worth $115K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Peter Blume-Jensen (CEO), with $31K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Acrivon Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ACRV

45 funds and institutions reported ACRV shares worth $38.1M at the end of Q2 2026, about 55% of the company. The largest holder is Ra Capital Management, L.P. with 31.6%.

Funds and institutions (13F) 55%Everyone else 45%

10 largest owners, by share of the company

Ra Capital Management, L.P.31.6%
Sands Capital Alternatives, LLC5.9%
Acadian Asset Management LLC3.0%
Vanguard Capital Management LLC2.5%
Wellington Management Group LLP2.3%
Renaissance Technologies LLC2.0%
Two Sigma Investments, LP1.7%
Marshall Wace, LLP1.4%
Bridgeway Capital Management, LLC1.0%
Geode Capital Management, LLC0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.12.23M31.56%$21.8M+47%
Sands Capital Alternatives, LLC2.29M5.91%$4.1M+8%
Acadian Asset Management LLC1.17M3.01%$2.1M+38%
Vanguard Capital Management LLC952,0082.46%$1.7M+32%
Wellington Management Group LLP888,1302.29%$1.6MNo change
Renaissance Technologies LLC758,8631.96%$1.4M+0%
Two Sigma Investments, LP641,4981.66%$1.1M+65%
Marshall Wace, LLP531,8561.37%$947K-5%
Bridgeway Capital Management, LLC378,9000.98%$674K+138%
Geode Capital Management, LLC265,2410.68%$472K+12%
BlackRock, Inc.239,1120.62%$426K+14%
Gsa Capital Partners LLP200,4150.52%$357K+7%
Vanguard Fiduciary Trust Co184,1280.48%$328K+71%
XTX Topco Ltd178,2390.46%$317K+166%
Jane Street Group, LLC74,6480.19%$133K-69%
Northern Trust Corp67,2020.17%$120K+37%
State Street Corp67,1450.17%$120KNo change
UBS Group AG43,8500.11%$78.1K+27%
Citadel Advisors LLC41,2760.11%$73.5KNew
Dimensional Fund Advisors LP29,3320.08%$52.2K+60%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ACRV insiders reported $115K of open-market purchases and $41.4K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$115K
3 trades, 3 people
Sales, 12 months
$41.4K
11 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 22, 2026
Filed Oct 26, 2026

Purchases and sales by month

$115K$115KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 22, 2026Mary MillerChief Legal OfficerSale513$1.84$944Form 4
Oct 5, 2026Mary MillerChief Legal OfficerSale294$1.99$585Form 4
Aug 25, 2026Peter Blume-Jensen +1CEOSale14,036$2.21$31KForm 4
Aug 18, 2026Katharine PetersonChief Accounting OfficerSale101$2.01$203Form 4
Aug 18, 2026Mary MillerChief Legal OfficerSale185$2.01$372Form 4
Aug 18, 2026Erick GamelinChief Development OfficeSale400$2.01$804Form 4
Aug 18, 2026Eric DevroeChief Operating OfficerSale604$2.01$1.2KForm 4
Aug 18, 2026Kristina Masson +1Vice presidentSale1,229$2.01$2.5KForm 4
Aug 18, 2026Kristina Masson +1Vice presidentSale484$2.01$973Form 4
Aug 4, 2026Adam D. LevyCFOSale1,142$1.57$1.8KForm 4
Jul 21, 2026Mary MillerChief Legal OfficerSale573$1.76$1KForm 4
Jan 14, 2026Peter Blume-Jensen +1CEOPurchase49,000$1.68$82.3KForm 4
Jan 14, 2026Adam D. LevyCFOPurchase8,832$1.70$15KForm 4
Jan 13, 2026Eric DevroeChief Operating OfficerPurchase10,000$1.72$17.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Peter Blume-JensenPresident and CEO, Director$82.3K$31KAug 25, 2026
Eric DevroeChief Operating Officer$17.2K$1.2KAug 18, 2026
Adam D. LevyChief Financial Officer$15K$1.8KAug 4, 2026
Kristina MassonEVP - Business Operations, Director–$3.4KAug 18, 2026
Mary MillerChief Legal Officer–$2.9KOct 22, 2026
Erick GamelinChief Development Officer–$804Aug 18, 2026
Katharine PetersonChief Accounting Officer–$203Aug 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ACRV short interest

Low short interest. 4.2% of ACRV shares are sold short: about 1 share in 24. Over the last 12 reports the number of shares short went down 28%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.80M ACRV shares were sold short, 4.2% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 158,681 shares, buying them all back would take about 11.4 trading days (days to cover).

Shares short, % of all shares

4.21%May 15Oct 308.03%

Days to cover

11.4May 15Oct 3012.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.80M4.21%+4%158,68111.4
Oct 15, 20261.74M4.05%+7%264,5386.6
Sep 30, 20261.62M3.77%+34%367,4694.4
Sep 15, 20261.20M2.81%+6%243,6024.9
Aug 31, 20261.14M2.66%-8%409,7412.8
Aug 14, 20261.24M2.88%-9%305,4734.0
Jul 31, 20261.36M3.50%-9%315,0554.3
Jul 15, 20261.49M3.84%-48%636,3792.3
Jun 30, 20262.84M7.33%+0%374,4937.6
Jun 15, 20262.83M7.30%+1%346,4618.2
May 29, 20262.80M7.23%+12%461,2476.1
May 15, 20262.50M6.44%+1%563,2114.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Acrivon Therapeutics company events

Acrivon Therapeutics filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementShared information with investors. Filing
  2. Nov 6, 2026AnnouncementAcrivon Therapeutics, Inc., a Delaware corporation, announced that it has entered into an asset purchase agreement with Aqilion AB, an unlisted Swedish public limited company (AB (publ); Sw. aktiebolag), registration number 556623-2095, pursuant to which the Company has acquired Aqilion’s programs… Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026LeadershipAcrivon Therapeutics, Inc. held its 2026 annual meeting of stockholders. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Mar 19, 2026ResultsReleased financial results. Filing
  7. Mar 2, 2026AgreementEnded an important agreement. Filing
  8. Feb 27, 2026AnnouncementShared information with investors. Filing
  9. Jan 8, 2026AnnouncementShared information with investors. Filing
  10. Jan 8, 2026AnnouncementThe Company announced the following clinical data: ACR-368: Potential First-in-Class CHK1 / CHK2 Inhibitor • In Arm 1 of the ACR-368 Phase 2b registrational-intent trial (monotherapy BM+ subjects) an updated interim analysis (EDC data extract as of December 4, 2025) showed a ORR of 39%*. In… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Acrivon Therapeutics financials

Famous investors that hold ACRV

2 of the 50 well-known investors we track reported holding ACRV in their latest 13F filing. The largest position is Ken Griffin's, worth $317K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026154,586$317K0.0%+275%
Jim Simons · Renaissance TechnologiesQ3 2026104,000$213K0.0%-86%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Acrivon Therapeutics, Inc. (ACRV) stock

Who owns the most ACRV stock?

The largest reported owner of Acrivon Therapeutics, Inc. (ACRV) is Ra Capital Management, L.P., with 31.6% of the company. In total, 45 funds and institutions reported holding ACRV at the end of Q2 2026, together about 55% of the shares. See the largest owners.

Are ACRV insiders buying or selling?

In the last 12 months, ACRV insiders reported 3 open-market purchases worth $115K and 11 sales worth $41.4K. The latest trade was on Oct 22, 2026. See every trade.

What is the short interest in ACRV?

As of Oct 30, 2026, 1.80M ACRV shares were sold short, 4.2% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 158,681 shares, buying them all back would take about 11.4 trading days (days to cover). See the history.

Which famous investors hold ACRV?

2 of the 50 well-known investors we track reported ACRV in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $317K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.